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Abstract
Diabetic eye diseases, such as diabetic retinopathy (DR) and diabetic macular 
edema (DME) are among the leading causes of blindness in developed countries. 
Anti-VEGF therapies such as, ranibizumab, aflibercept and off-label bevacizumab 
have become first-line treatment for DME. While randomized controlled trials 
show significant improvement in vision, these anti-VEGF agents have limited 
durability leading to a significant treatment burden, as reflected in real-world 
studies, which generally demonstrate under-treatment and less favorable visual 
acuity outcomes than observed in prospective trials. Alternative pathways, such as 
the Tie-2 angiopoietin pathway may address unmet needs, with potential for greater 
efficacy or durability when compared to anti-VEGF monotherapy. While some Tie-2 
angiopoietin therapeutic agents, such as nesvacumab, ARP-1536 or AKB-9778, did 
not meet primary endpoints in clinical trials, other agents have shown promise. 
One such agent is faricimab, a bispecific antibody inhibiting both VEGF-A and 
Ang-2. The phase 3 DME trials (YOSEMITE and RHINE) demonstrated favorable 
safety, visual, and durability outcomes; patients receiving faricimab injection every 
4 months achieved similar visual gains as those receiving aflibercept injection every 
2 months. Another agent, AXT107 is a peptide that inhibits VEGFR2 and modifies 
Ang-2 to behave more similarly to Ang-1, promoting vascular stability. This drug is 
currently undergoing phase 1/2a trials for safety and bioactivity to be completed in 
May 2022.
Keywords: diabetic retinopathy, diabetic macular edema, angiopoietins, Ang-2,  
Ang-1, Tie2 receptor, faricimab, AXT107, nesvacumab, AKB-9778, ARP-1536
1. Introduction
The global prevalence of diabetes and its comorbidities has rapidly increased, 
likely due to an aging population and a high prevalence of obesity [1]. As such, DR 
has become one of the leading causes of blindness within the Western World [2]. 
Several pooled analyses have disclosed the prevalence of DR within diabetic popula-
tions is greater than 30% [3]. Previously, diabetic macular edema (DME) resulted 
in approximately half of affected patients losing two or more lines of visual acuity 
within two years [4]. Historically, laser photocoagulation was validated in clinical 
trials to slow visual loss in patients with DME and proliferative diabetic retinopathy 
(PDR), an advanced form of DR involving neovascularization, potentially com-
plicated by vitreous hemorrhage, tractional retinal detachment, and neovascular 
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glaucoma. However, recent and continuing medical advancements in intravitreal 
corticosteroids and anti-vascular endothelial growth factor (VEGF) agents have led 
to improvements in clinical outcomes. This chapter reviews the current treatment 
options and those under development for diabetic eye disease specifically in the 
Tie-2/Angiopoietin vascular stability pathway.
2. Diabetic retinopathy pathophysiology
Chronic hyperglycemia, hyperlipidemia, and hypertension are involved in the 
development of DR [5]. Specifically chronic hyperglycemia has been linked to 
changes within the retinal microvasculature. Chronic hyperglycemia can result in 
damage through multiple mechanisms including osmotic alterations due to sorbitol 
accumulation from the polyol pathway, increased nonenzymatic glycosylation of 
proteins and reactive oxygen species, and activated protein kinase C [6]. These 
mechanisms contribute to dysfunction of endothelial cells and pericytes, ultimately 
leading to DR and potentially DME. Endothelial cells support the blood-retinal 
barrier and pericytes regulate capillary blood flow [7]. Damage to endothelial cells 
results in fluid accumulation in the macula [4, 8]. Damage to pericytes causes poor 
regulation of blood flow and microaneurysms within these vessels [9]. Ultimately, 
microvascular damage of the retina culminates in vision loss due to poor retinal 
perfusion and ischemia, upregulation of growth factors and inflammatory cyto-
kines, and angiogenesis [6, 10]. Among these growth factors and inflammatory 
cytokines, VEGF and angiopoietins play important roles and are targets of interest 
for therapeutic interventions [11].
3. Existing treatments: VEGF inhibitors, corticosteroids, and focal laser
VEGF proteins contribute to the regulation of vascular permeability and 
growth through tyrosine kinase receptors called VEGF receptors [12]. Binding of 
VEGF protein ligands to their VEGF receptors activates the mitogen-activating 
protein kinase (MAPK) signaling pathway and causes angiogenesis via increased 
endothelial cell growth and survival [13]. There are multiple VEGF proteins includ-
ing VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor 
(PlGF) [14]. VEGF-A primarily targets VEGF receptor 2 (VEGFR2) and increases 
angiogenesis, vascular permeability, and leukocyte adhesion [15, 16]. See Figure 1 
for a schematic of the relationship between the various VEGF ligands and receptors. 
Due to its significant role in the pathogenesis of DR/DME, many drugs inhibit the 
VEGF-A (referred to as simply VEGF for the remainder of this chapter) pathway to 
halt and decrease angiogenesis and vascular permeability within the disease [17]. 
Currently, two anti-VEGF medications are approved by the US Food and Drug 
Administration (FDA) for the treatment of DME: aflibercept (Eylea, Regeneron, 
Tarrytown, NY, USA) and ranibizumab (Lucentis, Genentech, South San Francisco, 
CA, UA). In addition, one anti-VEGF agent is frequently used off-label, bevaci-
zumab (Avastin, Genentech, South San Francisco, CA, USA).
Ranibizumab was originally approved for the treatment of neovascular age-
related macular degeneration (nAMD) in the United States in 2006, and it was 
approved for DME in 2012 based on the phase 3 RISE and RIDE studies [18]. It is 
administered intravitreally on a monthly basis. Aflibercept was approved in 2011 
for nAMD and in 2014 for DME after positive results from phase 3 VIVID and 
VISTA studies [19]. It can be dosed in longer eight-week intervals, after 5 monthly 
loading doses. Bevacizumab was approved in 2004 for use in metastatic colorectal 
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cancer; however, it is often used off-label for DME and is dosed intravitreally 
similarly to ranibizumab [20].
Intravitreal corticosteroids such as triamcinolone acetonide (Triescence, Alcon, Fort 
Worth, TX, USA), dexamethasone intravitreal implant (Ozurdex, Abbvie/Allergan, 
Irvine, CA, USA), and fluocinolone acetonide intravitreal implant (Iluvien, Alimera 
Sciences, Alpharetta, GA, USA) are also commonly used as a second line treatments for 
DME, and help reduce exudation by their broad inhibition of inflammatory cytokines. 
They are often used in combination with anti-VEGF therapy but have potential side 
effects of cataract progression and ocular hypertension [21]. Focal laser photocoagula-
tion to leaking microaneurysms in the macula has been shown to reduce vision loss 
compared to no treatment, but does not provide the visual acuity gains achieved with 
anti-VEGF therapy [19, 22].
Although the use of anti-VEGF agents has greatly improved treatment outcomes 
in DR/DME patients, these agents have limited durability and require dosing as 
frequently as monthly, which may be required indefinitely in some cases. Additional 
treatment barriers include limited treatment efficacy and financial burden, par-
ticularly for the branded agents [23]. Anti-VEGF therapy has shown lower efficacy 
in ‘real-world’ studies when compared to clinical trial outcomes in DME and in 
nAMD patients [24–26]. This is partially due to under-treatment in clinical practice, 
resulting in approximately one line less of visual acuity gains compared to large 
randomized clinical trials. One real world database study showed that over one 
year U.S. DME patients received a mean of 7.5, 7.9 and 7.7 injections of aflibercept, 
bevacizumab and ranibizumab, respectively, which is lower than the 9.2, 9.7, and 9.4 
injections received for these same drugs in the DRCR Protocol T Study [25, 27]. For 
the RISE and RIDE studies, DME patients received monthly ranibizumab injec-
tions (12 total), and for the VIVID and VISTA studies patients received bimonthly 
treatment of aflibercept after 5 monthly doses (8 total). Additionally, it has been 
shown that blockade of VEGF-A can lead to upregulation of other members of the 
VEGF family which also have pro-angiogenic effects [28]. For these reasons, there 
Figure 1. 
Schematic depiction of the major interactions between endothelial-specific growth factors and their receptors. 
(Reproduced here from https://commons.m.wikimedia.org/wiki/File:Endothelial_receptors_and_growth_
factors_01.png, licensed under the creative commons attribution-share alike 4.0 international license).
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has been a heightened focus on the development of medications that target alternate 
pathways, such as the Tie-2/angiopoietin pathway.
4. Tie-2/angiopoietin pathway
Recently, there has been great interest in drug development within the Tie-2 
transmembrane tyrosine kinase receptor pathway in exudative diseases such as 
DME and nAMD. This receptor is found on endothelial cells and is responsive to the 
opposing angiopoietins, Ang-1 and Ang-2 (see Figure 2) [29]. These growth factors 
are integral players in vessel homeostasis, permeability, and angiogenesis. Ang-1 
activates the Tie-2 receptor and leads to vascular stability [30]. Ang-2 acts as a com-
petitive antagonist to Ang-1, turning off the Tie-2 receptor, leading to abnormal 
vascular growth, leakage, and increased inflammatory signals within endothelial 
cells [31, 32]. Tumor necrosis factor α (TNFα), a central inflammation mediator, 
induces Ang-2 release from endothelial cells to enhance its stimulation of inflam-
mation and vascular leakage [33]. Additionally, the enzyme vascular endothelial 
protein tyrosine phosphatase (VE-PTP) inactivates the Tie-2 receptor and therefore 
interferes with the vascular stabilizing effects of Ang-1 [34].
A number of preclinical studies have supported the importance of the Tie-2/
Ang-2 pathways in DR and DME pathophysiology. Studies in the developing retina 
and in ischemic retinal mouse models have shown increased expression of both 
Ang-2 and VEGF which correlated to increased neovascularization [35, 36]. A study 
in double transgenic mice expressing both Ang-1 and VEGF showed that increased 
expression of Ang-1 led to decreased neovascularization and suppression of VEGF 
[37]. Additionally, high levels of Ang-2 and VEGF have been found in samples 
from diabetic patients following vitrectomy [38, 39]. During times of stress such 
as, hyperglycemia, ischemia, and oxidative stress, Ang-2 levels increase and result 
in aberrant vascular leakage and growth. Therapeutic interventions for exuda-
tive diseases may focus on inhibiting Ang-2 or VE-PTP therefore preventing their 
counterregulatory effects on the Tie-2 receptor.
4.1 Faricimab
Faricimab, previously RG7716 (Roche, Basel, Switzerland and Genentech, 
South San Francisco, CA, USA) is a bispecific antibody that binds to and inhibits 
both VEGF and Ang-2. Phase 1 and 2 trials showed promising results, supporting 
advancement to phase 3 trials [40, 41]. Results from four phase 3 trials from both 
patients with DR/DME and nAMD were released in February, 2021 from Roche 
[42]. All four studies demonstrated non-inferior results when administered in long-
lasting dosing intervals compared to aflibercept.
Figure 2. 
Molecular targets and approaches to re-establish homeostasis in Ang–Tie-2 and VEGF–VEGFR pathways 
(reproduced with permission from [9]).
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The YOSEMITE and RHINE studies are two identical phase 3 clinical studies 
that compared faricimab to aflibercept in patients with DME. The YOSEMITE and 
RHINE trials enrolled 940 and 951 patients respectively. These studies compared 
faricimab 6.0 mg given at individualized intervals (one, two, three or four months 
based on DR activity), faricimab 6.0 mg given at two-month intervals, and afliber-
cept 2.0 mg given at two-month intervals. Sham injections were given when patients 
within a treatment group were not scheduled to receive treatment to maintain 
blinding. The primary outcomes were average change in best corrected visual acuity 
(BCVA) at one year. Secondary outcomes were percent of individualized interval 
arm receiving doses at one, two, three, and four months at 52 weeks, percent of 
participants with a two-step or more improvement in diabetic retinopathy severity 
score (DRSS) from baseline, percent of participants with gain and percent without 
loss of 15 letters or more in BCVA, and change in central subfield thickness [43, 44].
YOSEMITE showed an average improvement of +11.6 ETDRS letters in the indi-
vidualized interval faricimab arm, +10.7 ETDRS letters in the two-month interval 
faricimab arm, and +10.9 ETDRS letters in the aflibercept arm. Similarly, RHINE 
showed an average improvement of +10.8 ETDRS letters in the individualized 
interval faricimab arm, +11.8 ETDRS letters in the two-month interval faricimab 
arm, and +10.3 ETDRS letters in the aflibercept arm. Within the individualized 
interval faricimab arm, there were 151/286 (52.8%) participants in YOSEMITE 
that were dosed with a four-month interval at one year and 60/286 (21%) that were 
dosed with a three-month interval. Similarly, in RHINE, 157/308 (51%) participants 
were dosed with a four-month interval at one year and 62/308 (20.1%) achieved 
a three-month dosing interval. When compared to the aflibercept two-month 
dosing interval arm, both studies showed that the participants that achieved up to 
four-month dosing intervals of faricimab had larger reductions in central subfield 
thickness (CST) [42]. Roche has announced plan to submit a new drug application 
to the U.S. Food and Drug Administration and the European Medicines Agency for 
the treatment of DME and nAMD.
4.2 AXT107
AXT107 (Asclepix Therapeutics, Baltimore, MD, USA) is a peptide that modi-
fies Ang-2 to function more similarly to Ang-1. This peptide is derived from the 
non-collagenous domain of collagen IV and ultimately activates the Tie-2 receptor 
and stabilizes vascular permeability [9]. In studies using confluent monolayers of 
endothelial cells, AXT107 attached to Ang-2 binds to the Tie-2 receptor and disrupts 
α5β1 integrin, causing Tie-2 and α5 to move to cell junctions. Ultimately, Ang-2 
modified by AXT107 serves as an agonist of the now junctional Tie-2 receptor and 
acts similarly to Ang-1 even in the presence of low concentrations of Ang-1 [45]. 
AXT107 also suppresses TNF-α induced vascular inflammation in endothelial 
cells, which may provide additional benefit in treating the chronic inflammatory 
component of DME and other retinal vascular diseases [33]. Additionally, in animal 
models, AXT107 increased breakdown of VEGFR2 which ultimately decreases the 
effects of VEGF [46]. Studies conducted in rabbit eyes injected AXT107 into the 
vitreous as a clear gel depot. This gel formulation slowly releases the AXT107 and 
could potentially decrease the need for many repeat injections. The rabbit model 
studies showed that AXT107 decreased leakage by 86% and 70% at one and two 
months, respectively. This was compared to aflibercept which reduced leakage by 
69% at one month and did not reduce leakage at two months [47].
The CONGO study is a phase 1/2a clinical trial that will evaluate the safety and 
bioactivity of AXT107. This is a non-randomized open label study with 18 partici-
pants with DME. Three treatment arms of low (0.1 mg), medium (0.25 mg), and 
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high (0.5 mg) doses are included. The primary outcome is safety measured by inci-
dence of adverse effects. Secondary outcomes are efficacy assessed by change in CST, 
change in BCVA, and percentage of participants improving by greater than 5, 10, 15 
letters on the eye chart. This study is expected to be concluded by May 2022 [48].
4.3 Nesvacumab
Nesvacumab (Regeneron, Tarrytown, NY, USA) is a human immunoglobulin 
G1 (IgG1) monoclonal antibody that binds to and blocks Ang-2. Nesvacumab 
was coformulated with aflibercept and phase 1 trials showed promising results 
for nAMD and DME. The phase 2 ONYX (nAMD) and RUBY (DME) trials did 
not duplicate that success however; patients treated with nesvacumab-aflibercept 
combo did not show any significant benefit in BCVA or CST compared to afliber-
cept monotherapy. For the RUBY study, however, there was a significant differ-
ence in the proportion of patients with resolution of foveal edema and ≥2 step 
improvement in DRSS in the high dose co-formulation arm [49]. In 2017, Regeneron 
announced that Nesvacumab would not advance to phase 3 trials [50].
4.4 AKB-9778
AKB-9778 (Aerpio Pharmaceuticals, Cincinnati, OH, USA) is an antagonist of 
VE-PTP given via subcutaneous injection. The TIME-2a study was a phase 2 study 
that sought to determine the safety and efficacy of AKB-9778 in DME patients. 
There were three treatment arms within 144 participants: 15 mg AKB-9778 twice 
daily and monthly placebo intravitreal injections, 15 mg AKB-9778 twice daily and 
monthly 0.3 mg ranibizumab intravitreal injections, and placebo subcutaneous 
injection twice daily and monthly 0.3 mg ranibizumab injections. The primary 
outcome was mean change in CST at three months and secondary outcomes were 
BCVA, DRSS, and safety [51]. Mean change CST was significantly greater in 
participants receiving both AKB-9778 and ranibizumab (−164.4±24.2 μm) than in 
participants receiving ranibizumab alone (−110.4±17.2 μm). Regarding the second-
ary outcomes, the percentage of participants that gained ≥10 or ≥15 letters across 
the treatment arms were: 8.7% and 4.3% in the AKB-9778 alone group, 29.8% and 
17.0% in the ranibizumab along group, and 35.4% and 20.8% in the combination 
group, respectively. The DRSS remained similar across the three groups and AKB-
9778 was found to be safe [52].
The safety and efficacy of AKB-9778 in 167 patients with nonproliferative DR 
was studied in the Time-2b study. This study did not utilize anti-VEGF therapy 
in its treatment arms and instead used AKB-9778 alone. The treatment arms 
included: AKB-9778 15 mg once daily, AKB-9778 15 mg twice daily, and subcu-
taneous placebo injected twice daily [53]. The primary outcome of percentage of 
participants with improvement in their DRSS was not met at 48 weeks. There was a 
significant 20% improvement in urine albumin creatinine ratio in patients treated 
with AKB-9778 twice daily and there was also a significant reduction in intraocular 
pressure among the treatment groups versus placebo. Based on these results, Aerpio 
Pharmiceuticals is investigating the use of AKB-9778 in diabetic nephropathy and 
open angle glaucoma. AKB-9778 is also in a phase 2 study for use in hospitalized 
subjects with COVID-19 acute respiratory distress syndrome [54].
4.5 ARP-1536
ARP-1536 (Aerpio Pharmiceuticals, Cincinnati, OH, USA) has the same biologic 
activity as AKB-9778 however it is delivered by intravitreal injection rather than 
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subcutaneously. ARP-1536 is an antagonist to VE-PTP which activates the Tie-2 
receptor and provides vascular stability. It is in pre-clinical studies in combination 
with anti-VEGF therapy for DME and wet AMD [54].
5. Conclusion
Diabetic eye diseases are among the leading causes of blindness within the 
Western world. Previously, laser photocoagulation was the mainstay of treatment 
for DME and PDR [55]. Over the past two decades, anti-VEGF agents have become 
first-line treatments for DME. Although these medications have significantly 
improved visual outcomes for DME, limitations have been noted in ‘real-world’ 
studies [24–26]. Most notably, anti-VEGF agents require frequent injection, which 
acts as a treatment barrier to patients and leads to under-dosing. The investigational 
drugs that target the Tie-2/angiopoietin pathway may produce greater drying effect 
on the macula, with prolonged durability and superior visual outcomes compared 
to anti-VEGF monotherapy. Future trials may focus on the ability of combination 
anti-VEGF and Ang-2 inhibitors to treat PDR.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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